The successful completion of third-party testing for China Pharma Holdings' therapeutic device is a critical step in the regulatory process and can lead to increased investor confidence in the company's ability to bring new products to market. This development is likely to have a positive impact on the stock price in the short term as it reduces the regulatory risk and demonstrates progress in product development.